Intermediatebiotechnology
Stem Cells and Genetics
Overview
Stem cells self-renew and differentiate: totipotent (zygote), pluripotent (ESCs/iPSCs: any cell type), multipotent (hematopoietic: blood lineages), unipotent. Genetic circuits (Oct4/Sox2/Nanog in pluripotency; lineage master TFs in differentiation) control fate; niche signals maintain stemness. Applications: bone-marrow transplant (standard), emerging iPSC therapies, and disease modeling.
Learning objectives
- Define potency levels with examples
- Explain pluripotency transcription factor networks
- Describe stem-cell niches
- List clinical applications and challenges
The potency hierarchy
Totipotent: zygote/early blastomeres (whole organism + placenta). Pluripotent: embryonic stem cells, iPSCs (all body cell types, not placenta). Multipotent: hematopoietic stem cells (blood), neural stem cells. Unipotent: spermatogonial stem cells. Potency narrows as epigenetic marks accumulate.
Each step down the hierarchy closes epigenetic doors.
Genetic control of pluripotency
Oct4, Sox2, Nanog form a self-reinforcing circuit activating pluripotency genes and repressing differentiation; Polycomb keeps lineage genes poised (bivalent domains). Differentiation = master TFs (MyoD for muscle, GATA1 for erythroid) collapsing the circuit toward one fate.
Oct4/Sox2/Klf4/c-Myc force the pluripotency circuit on in adult cells: iPSCs.
Niches
Stem cells live in microenvironments supplying maintenance signals: HSCs in bone-marrow niches (osteoblasts, CXCL12), intestinal crypts (Wnt from Paneth cells), hair follicles. Remove the niche signals and stem cells differentiate or die: identity is partly extrinsic.
A stem cell outside its niche loses stemness: transplantation must recreate or find niches.
Medicine: now and next
Now: hematopoietic stem-cell transplant for leukemias, immunodeficiencies, sickle cell (standard for decades). Next: iPSC-derived retinal cells (AMD trials), dopaminergic neurons (Parkinson's), pancreatic beta cells (diabetes), lab-grown blood. Challenges: tumorigenicity (c-Myc, residual pluripotent cells), immune rejection, cost.
Bone-marrow transplant (1950s-70s) was stem-cell therapy before the term existed.
Key points
- Totipotent -> pluripotent -> multipotent -> unipotent: narrowing options
- Oct4/Sox2/Nanog circuit maintains pluripotency; master TFs drive fates
- Niches provide extrinsic maintenance signals
- HSCT is standard; iPSC therapies for retina, Parkinson's, diabetes in trials
Common misconceptions
✓ Truth: ESC lines derive from surplus IVF blastocysts donated for research; iPSCs now avoid embryos entirely.
✓ Truth: Adult stem cells are multipotent (lineage-restricted); only pluripotent cells have broad potential, with tumor risk.
Practice questions
Q1. Pluripotent stem cells can become
- Only blood
- Any body cell type
- Only placenta
- Nothing
All somatic lineages, but not extraembryonic tissue (that's totipotency).
Q2. The core pluripotency factors include
- Insulin and glucagon
- Oct4, Sox2, Nanog
- p53 and Rb
- Actin and myosin
The self-reinforcing OSN circuit defines pluripotency.
Q3. The longest-established stem-cell therapy is
- iPSC retina
- Hematopoietic stem-cell transplantation
- Hair cloning
- Brain transplants
Bone-marrow transplant: standard care since the 1970s-80s.
Click a question to reveal the answer and explanation.
Frequently asked questions
Why is c-Myc risky in iPSCs?
It's an oncogene: reactivation can transform; Myc-free reprogramming cocktails are preferred clinically.
What is the Hayflick limit's relevance?
Differentiated cells senesce; stem cells' telomerase lets them self-renew long-term.
How are iPSCs used in disease modeling?
Patient iPSCs differentiated into affected cell types (neurons, cardiomyocytes) reveal disease mechanisms and screen drugs.